Przejdź do trybu offline z Player FM !
Matthew C. Ehrlich, "The Krebiozen Hoax: How a Mysterious Cancer Drug Shook Organized Medicine" (U Illinois Press, 2024)
Manage episode 439328757 series 2421458
The brainchild of an obscure Yugoslav physician, Krebiozen emerged in 1951 as an alleged cancer treatment. Andrew Ivy, a University of Illinois vice president and a famed physiologist dubbed “the conscience of U.S. science,” wholeheartedly embraced Krebiozen. Ivy’s impeccable credentials and reputation made the treatment seem like another midcentury medical miracle. But after years of controversy, the improbable saga ended with Krebiozen proved a sham, its inventor fleeing the country, and Ivy’s reputation and legacy in ruins.
Matthew C. Ehrlich’s history of Krebiozen tells a quintessential story of quackery. Though most experts dismissed the treatment, it found passionate public support not only among cancer patients but also people in good health. The treatment’s rise and fall took place against the backdrop of America’s never-ending suspicion of educational, scientific, and medical expertise. In addition, Ehrlich examines why people readily believe misinformation and struggle to maintain hope in the face of grave threats to well-being.
A dramatic account of fraud and misplaced trust, The Krebiozen Hoax: How a Mysterious Cancer Drug Shook Organized Medicine (U Illinois Press, 2024) shines a light on a forgotten medical scandal and its all-too-familiar relevance in the twenty-first century.
Matthew C. Ehrlich is professor emeritus of journalism at the University of Illinois. He has previously published five books including Dangerous Ideas on Campus: Sex, Conspiracy, and Academic Freedom in the Age of JFK and Kansas City vs. Oakland: The Bitter Sports Rivalry That Defined an Era.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/eastern-european-studies
986 odcinków
Manage episode 439328757 series 2421458
The brainchild of an obscure Yugoslav physician, Krebiozen emerged in 1951 as an alleged cancer treatment. Andrew Ivy, a University of Illinois vice president and a famed physiologist dubbed “the conscience of U.S. science,” wholeheartedly embraced Krebiozen. Ivy’s impeccable credentials and reputation made the treatment seem like another midcentury medical miracle. But after years of controversy, the improbable saga ended with Krebiozen proved a sham, its inventor fleeing the country, and Ivy’s reputation and legacy in ruins.
Matthew C. Ehrlich’s history of Krebiozen tells a quintessential story of quackery. Though most experts dismissed the treatment, it found passionate public support not only among cancer patients but also people in good health. The treatment’s rise and fall took place against the backdrop of America’s never-ending suspicion of educational, scientific, and medical expertise. In addition, Ehrlich examines why people readily believe misinformation and struggle to maintain hope in the face of grave threats to well-being.
A dramatic account of fraud and misplaced trust, The Krebiozen Hoax: How a Mysterious Cancer Drug Shook Organized Medicine (U Illinois Press, 2024) shines a light on a forgotten medical scandal and its all-too-familiar relevance in the twenty-first century.
Matthew C. Ehrlich is professor emeritus of journalism at the University of Illinois. He has previously published five books including Dangerous Ideas on Campus: Sex, Conspiracy, and Academic Freedom in the Age of JFK and Kansas City vs. Oakland: The Bitter Sports Rivalry That Defined an Era.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/eastern-european-studies
986 odcinków
Wszystkie odcinki
×Zapraszamy w Player FM
Odtwarzacz FM skanuje sieć w poszukiwaniu wysokiej jakości podcastów, abyś mógł się nią cieszyć już teraz. To najlepsza aplikacja do podcastów, działająca na Androidzie, iPhonie i Internecie. Zarejestruj się, aby zsynchronizować subskrypcje na różnych urządzeniach.